

RNF139 Blocking Peptide (C-Term)
Synthetic peptide
Catalog # BP21873b**Specification**

RNF139 Blocking Peptide (C-Term) - Product Information

Primary Accession [Q8WU17](#)
Other Accession [Q5RBT7](#)

RNF139 Blocking Peptide (C-Term) - Additional Information

Gene ID 11236

Other Names

E3 ubiquitin-protein ligase RNF139, 632-, RING finger protein 139, Translocation in renal carcinoma on chromosome 8 protein, RNF139 (HGNC:17023)

Target/Specificity

The synthetic peptide sequence is selected from aa 624-636 of HUMAN RNF139 (HGNC:17023)

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

RNF139 Blocking Peptide (C-Term) - Protein Information

Name RNF139 ([HGNC:17023](#))

Function

E3-ubiquitin ligase; acts as a negative regulator of cell proliferation through mechanisms involving G2/M arrest and cell death (PubMed:10500182, PubMed:12032852, PubMed:17016439). Required for MHC class I ubiquitination in cells expressing the cytomegalovirus protein US2 before dislocation from the endoplasmic reticulum (ER) (PubMed:19720873). Affects SREBP processing by hindering the SREBP-SCAP complex translocation from the ER to the Golgi, thereby reducing SREBF2 target gene expression (PubMed:<a

[19706601](http://www.uniprot.org/citations/19706601), PubMed: [20068067](http://www.uniprot.org/citations/20068067)). Involved in the sterol-accelerated degradation of HMGCR (PubMed: [22143767](http://www.uniprot.org/citations/22143767), PubMed: [23223569](http://www.uniprot.org/citations/23223569)). This is achieved through binding of RNF139 to INSIG1 and/or INSIG2 at the ER membrane (PubMed: [22143767](http://www.uniprot.org/citations/22143767)). In addition, interaction of RNF139 with AUP1 facilitates interaction of RNF139 with ubiquitin-conjugating enzyme UBE2G2 and ubiquitin ligase AMFR, leading to ubiquitination of HMGCR (PubMed: [23223569](http://www.uniprot.org/citations/23223569)). The ubiquitinated HMGCR is then released from the ER into the cytosol for subsequent destruction (PubMed: [22143767](http://www.uniprot.org/citations/22143767), PubMed: [23223569](http://www.uniprot.org/citations/23223569)). Required for INSIG1 ubiquitination (PubMed: [20068067](http://www.uniprot.org/citations/20068067)). May be required for EIF3 complex ubiquitination (PubMed: [20068067](http://www.uniprot.org/citations/20068067)).

Cellular Location

Endoplasmic reticulum membrane; Multi-pass membrane protein

Tissue Location

Highly expressed in testis, placenta and adrenal gland. Moderate expression in heart, brain, liver, skeletal muscle and pancreas, and low expression in lung and kidney

RNF139 Blocking Peptide (C-Term) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

RNF139 Blocking Peptide (C-Term) - Images

RNF139 Blocking Peptide (C-Term) - Background

E3-ubiquitin ligase; acts as a negative regulator of the cell proliferation through mechanisms involving G2/M arrest and cell death. Required for MHC class I ubiquitination in cells expressing the cytomegalovirus protein US2 before dislocation from the endoplasmic reticulum (ER). Affects SREBP processing by hindering the SREBP/SCAP complex translocation from the ER to the Golgi, thereby reducing SREBF2 target gene expression. Required for INSIG1 ubiquitination. May be required for EIF3 complex ubiquitination. May function as a signaling receptor.

RNF139 Blocking Peptide (C-Term) - References

Gemmill R.M., et al. Proc. Natl. Acad. Sci. U.S.A. 95:9572-9577(1998).
Ota T., et al. Nat. Genet. 36:40-45(2004).
Mural R.J., et al. Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
Lorick K.L., et al. Proc. Natl. Acad. Sci. U.S.A. 96:11364-11369(1999).
Gemmill R.M., et al. Oncogene 21:3507-3516(2002).